These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1418 related articles for article (PubMed ID: 16413079)

  • 1. Gene silencing through RNA interference (RNAi) in vivo: strategies based on the direct application of siRNAs.
    Aigner A
    J Biotechnol; 2006 Jun; 124(1):12-25. PubMed ID: 16413079
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polyethylenimines for RNAi-mediated gene targeting in vivo and siRNA delivery to the lung.
    Günther M; Lipka J; Malek A; Gutsch D; Kreyling W; Aigner A
    Eur J Pharm Biopharm; 2011 Apr; 77(3):438-49. PubMed ID: 21093588
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hydrodynamic delivery protocols.
    Rychahou PG; Evers BM
    Methods Mol Biol; 2010; 623():189-95. PubMed ID: 20217552
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nonviral in vivo delivery of therapeutic small interfering RNAs.
    Aigner A
    Curr Opin Mol Ther; 2007 Aug; 9(4):345-52. PubMed ID: 17694447
    [TBL] [Abstract][Full Text] [Related]  

  • 5. RNAi-mediated gene-targeting through systemic application of polyethylenimine (PEI)-complexed siRNA in vivo.
    Urban-Klein B; Werth S; Abuharbeid S; Czubayko F; Aigner A
    Gene Ther; 2005 Mar; 12(5):461-6. PubMed ID: 15616603
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Atelocollagen-mediated local and systemic applications of myostatin-targeting siRNA increase skeletal muscle mass.
    Kinouchi N; Ohsawa Y; Ishimaru N; Ohuchi H; Sunada Y; Hayashi Y; Tanimoto Y; Moriyama K; Noji S
    Gene Ther; 2008 Aug; 15(15):1126-30. PubMed ID: 18323791
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A low molecular weight fraction of polyethylenimine (PEI) displays increased transfection efficiency of DNA and siRNA in fresh or lyophilized complexes.
    Werth S; Urban-Klein B; Dai L; Höbel S; Grzelinski M; Bakowsky U; Czubayko F; Aigner A
    J Control Release; 2006 May; 112(2):257-70. PubMed ID: 16574264
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Polyethylenimine PEI F25-LMW allows the long-term storage of frozen complexes as fully active reagents in siRNA-mediated gene targeting and DNA delivery.
    Höbel S; Prinz R; Malek A; Urban-Klein B; Sitterberg J; Bakowsky U; Czubayko F; Aigner A
    Eur J Pharm Biopharm; 2008 Sep; 70(1):29-41. PubMed ID: 18499413
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vivo pharmacokinetics, tissue distribution and underlying mechanisms of various PEI(-PEG)/siRNA complexes.
    Malek A; Merkel O; Fink L; Czubayko F; Kissel T; Aigner A
    Toxicol Appl Pharmacol; 2009 Apr; 236(1):97-108. PubMed ID: 19371615
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RNA interference-mediated gene silencing of pleiotrophin through polyethylenimine-complexed small interfering RNAs in vivo exerts antitumoral effects in glioblastoma xenografts.
    Grzelinski M; Urban-Klein B; Martens T; Lamszus K; Bakowsky U; Höbel S; Czubayko F; Aigner A
    Hum Gene Ther; 2006 Jul; 17(7):751-66. PubMed ID: 16839274
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of siRNA nuclease stability on the in vitro and in vivo kinetics of siRNA-mediated gene silencing.
    Bartlett DW; Davis ME
    Biotechnol Bioeng; 2007 Jul; 97(4):909-21. PubMed ID: 17154307
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Polyethylenimine (PEI)/siRNA-mediated gene knockdown in vitro and in vivo.
    Höbel S; Aigner A
    Methods Mol Biol; 2010; 623():283-97. PubMed ID: 20217558
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vivo gene silencing in solid tumors by targeted electrically mediated siRNA delivery.
    Golzio M; Mazzolini L; Ledoux A; Paganin A; Izard M; Hellaudais L; Bieth A; Pillaire MJ; Cazaux C; Hoffmann JS; Couderc B; Teissié J
    Gene Ther; 2007 May; 14(9):752-9. PubMed ID: 17344906
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Polyethylenimine/small interfering RNA-mediated knockdown of vascular endothelial growth factor in vivo exerts anti-tumor effects synergistically with Bevacizumab.
    Höbel S; Koburger I; John M; Czubayko F; Hadwiger P; Vornlocher HP; Aigner A
    J Gene Med; 2010 Mar; 12(3):287-300. PubMed ID: 20052738
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Harnessing RNA interference to develop neonatal therapies: from Nobel Prize winning discovery to proof of concept clinical trials.
    DeVincenzo JP
    Early Hum Dev; 2009 Oct; 85(10 Suppl):S31-5. PubMed ID: 19833462
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nonviral vector-mediated RNA interference: its gene silencing characteristics and important factors to achieve RNAi-based gene therapy.
    Takahashi Y; Nishikawa M; Takakura Y
    Adv Drug Deliv Rev; 2009 Jul; 61(9):760-6. PubMed ID: 19386274
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RNA interference (RNAi) in hematology.
    Scherr M; Steinmann D; Eder M
    Ann Hematol; 2004 Jan; 83(1):1-8. PubMed ID: 14574462
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Toxicogenomics of non-viral drug delivery systems for RNAi: potential impact on siRNA-mediated gene silencing activity and specificity.
    Akhtar S; Benter I
    Adv Drug Deliv Rev; 2007 Mar; 59(2-3):164-82. PubMed ID: 17481774
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exploring cell type-specific internalizing antibodies for targeted delivery of siRNA.
    Liu B
    Brief Funct Genomic Proteomic; 2007 Jun; 6(2):112-9. PubMed ID: 17670766
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effective inhibition of hepatitis B virus replication by small interfering RNAs expressed from human foamy virus vectors.
    Sun Y; Li Z; Li L; Li J; Liu X; Li W
    Int J Mol Med; 2007 Apr; 19(4):705-11. PubMed ID: 17334648
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 71.